engleski

Assessment of Alopecia in Cancer Patients Treated with CDK 4/6 Inhibitors and Antihormonal Therapy According to Patient Related Outcomes at the University Hospital for Tumors

Selective cyclin-dependent kinases 4/6 (CDK 4/6) inhibitors, in addition to endocrine therapy, are standard of care for metastatic hormone receptor (HR) positive HER-2 negative breast cancer for the last few years. These agents have acceptable and easily manageable adverse events. Alopecia is one of the fre- quent adverse events that remarkably affect patients’ quality of life, but is equally neglected. There is only one systematic review and meta-analysis that discuss this issue. This study aims to discuss and evaluate the alopecia in patients with hormone-positive, HER-2 nega- tive metastatic disease with the patient-related outcome (PRO) and by the European Organization for Research and Treatment of Cancer Quality of life Questionnaire - BR23 (EORTC-QLQ- BR23). We obtained data from 158 patients with HR-positive HER-2 negative breast cancer who were treated at the Division of Medical Oncology with ribociclib or palbociclib and endocrine therapy, in the period from 08/2018 to 12/2020 and had alopecia as an adverse event. Patients had to complete at least one four- week cycle of therapy and necessitate fill in the questionnaires. For further analysis 149 of them were eli- gible, all female patients. During therapy with ribociclib, around 55% of patients had reported alopecia as an adverse event, whilst during therapy with palbociclib around 45% of patients. This is somewhat more than data on alopecia mentioned in the PALOMA 3 QoL assessment, yet in line with the data in the mentioned systematic review, and serves as warning and reminder of this for patients difficult symptom, because of its possible severe distress potential. It is not a life-threatening adverse event, but it directly contributes to worsening of patients’ quality of life.

HR+ breast cancer, CDK 4/6 inhibitors, alopecia

nije evidentirano